#oncologydrug — Public Fediverse posts

https://www.europesays.com/ch/135991/ Novartis (SWX:NOVN) Lands Global Radioligand Therapy License To Deepen Cancer Pipeline #BoomRayPharmaceuticals #Novartis #OncologyDrug #RadioligandTherapy

GSK Presents Jideytro Data for Potential Use in First-Line NSCLC

GSK plc GSK announced positive data from the registrational phase I/II ARROS-1 study evaluating its oncology drug, Jideytro…
#EuropeSays #Britain #Europe #EU #GSK #GSKplc #Jideytro #nsclc #OncologyDrug #Patients #ZacksInvestmentResearch #ZacksRank
https://www.europesays.com/britain/123943/

https://www.europesays.com/britain/123943/ GSK Presents Jideytro Data for Potential Use in First-Line NSCLC #GSK #GSKPlc #Jideytro #nsclc #OncologyDrug #Patients #ZacksInvestmentResearch #ZacksRank

GSK’s sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer

GSK plc GSK announced that the FDA has accepted for review its supplemental biologics license application (sBLA) seeking approval…
#EuropeSays #Britain #Europe #EU #GSK #AnikaTherapeutics #FDA #GSKplc #Jemperli #NationalPriorityVoucher #OncologyDrug #rectalcancer #sBLA #ZacksInvestmentResearch
https://www.europesays.com/britain/110015/

https://www.europesays.com/britain/110015/ GSK’s sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer #AnikaTherapeutics #FDA #GSK #GSKPlc #Jemperli #NationalPriorityVoucher #OncologyDrug #RectalCancer #sBLA #ZacksInvestmentResearch

GSK wins FDA nod for Jideytro lung cancer drug | GSK SEC Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER…
#EuropeSays #Britain #Europe #EU #GSK #ARROS-1clinicaltrial #FDAapproval #GSK6-K #Jideytro #Nuvalentacquisition #OncologyDrug #ROS1-positiveNSCLC #zidesamtinib
https://www.europesays.com/britain/88610/

https://www.europesays.com/britain/88610/ GSK wins FDA nod for Jideytro lung cancer drug | GSK SEC Filing #ARROS1ClinicalTrial #FDAApproval #GSK #GSK6K #Jideytro #NuvalentAcquisition #OncologyDrug #ROS1PositiveNSCLC #zidesamtinib

GSK’s Jemperli Delivers Promising Interim Data in Rectal Cancer

GSK plc GSK has announced positive interim data from a mid-stage study evaluating its oncology drug, Jemperli (dostarlimab), in…
#EuropeSays #Britain #Europe #EU #GSK #approvedindications #endometrialcancers #GSKplc #Jemperli #mismatchrepair #OncologyDrug #Patients #rectalcancer #ZacksInvestmentResearch
https://www.europesays.com/britain/83022/

https://www.europesays.com/britain/83022/ GSK’s Jemperli Delivers Promising Interim Data in Rectal Cancer #ApprovedIndications #EndometrialCancers #GSK #GSKPlc #Jemperli #MismatchRepair #OncologyDrug #Patients #RectalCancer #ZacksInvestmentResearch

AstraZeneca licenses lung cancer drug Zegfrovy | AZN SEC Filing

FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant…
#EuropeSays #Britain #Europe #EU #AstraZeneca #AZN #EGFRexon20 #licenseagreement #non-smallcelllungcancer #OncologyDrug #royaltydeal #Sunvozertinib #Zegfrovy
https://www.europesays.com/britain/82757/

https://www.europesays.com/britain/82757/ AstraZeneca licenses lung cancer drug Zegfrovy | AZN SEC Filing #AstraZeneca #AZN #EGFRExon20 #LicenseAgreement #NonSmallCellLungCancer #OncologyDrug #RoyaltyDeal #Sunvozertinib #Zegfrovy

https://www.europesays.com/britain/79975/ Southeast Asia Oncology Drug Access Market Now Available; Profiles Roche, AstraZeneca, Merck, and Other Key Peers #Access #AccessMarket #AstraZeneca #MarketGrowth #MarketInsights #MarketSegmentation #OncologyDrug #OncologyDrugs #PatientAccess #PharmaceuticalCompanies #PrecisionMedicine #SoutheastAsia #StrategicInsights

https://www.europesays.com/ch/100628/ Southeast Asia Oncology Drug Access Market Now Available; Profiles Roche, AstraZeneca, Merck, and Other Key Peers #access #AccessMarket #MarketGrowth #MarketInsights #MarketSegmentation #OncologyDrug #OncologyDrugs #PatientAccess #PharmaceuticalCompanies #PrecisionMedicine #Roche #SoutheastAsia #StrategicInsights